Search

Author Index

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

 

H
Haagsma E. B. - High-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in congenital coagulation disorders. A randomized, double-blind, placebo-controlled clinical trial
Haas S. - Prevention of venous thromboembolism in orthopedic trauma patients receiving heparin thromboprophylaxis – a substudy analysis of autopsy-confirmed fatal pulmonary embolism
Haas S. - Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications
  - HIT Type II a clinically heterogenous, hypercoagulable state: why promp intervention is critical
  - Oral direct thrombin inhibition, a promising new approach
Haas F. - Elevated levels of d-dimer and fragment 1 + 2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis
Haas S. - A risk assessment model for identifying medical patients who should receive thromboprophylaxis
Haas R. - Arterial thromboembolic complications in children
Haas De M. - The epitope of the CD109 monoclonal antibody 8A3 overlaps with the epitope of Gov antibodies: implications for Gov antibody detection
Haase K. K. - TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
  - Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
  - Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
  - The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
  - MCP-1 as early marker for cell activation in septic patients
Habart D. - Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
  - Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
  - Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
  - In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients
  - An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
  - Good efficacy of low dosing regimen of a FVIII/vWF concentrate in patients with von Willebrand disease
Habart D. - The C1 domain substitution His2155Asp severely reduces factor VIII binding to von Willebrand factor
  - Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe haemophilia A in the Czech Republic
  - A human factor VIII inhibitor tolerating the endogenous FVIII with a unique A2 domain substitution in CRM + hemophilia A
  - The anti-thrombin variant -6Arg is a silent mutation
Habenicht A. - Evidence for a functionally active protease-activated receptor-3 in human vascular smooth muscle cells
Haberal M. - Role of genetic factors in vascular access thrombosis
Haberichter S. L. - Assay of the von Willebrand factor propeptide in patients with type 1 von Willebrand disease (VWD) and the identification of patients with a S2179F mutation in the D4 region of von Willebrand factor
Haberichter S. L. - The sorting signal for von Willebrand factor (vWF) granular storage lies within the first 140 amino acids of the D2 domain of the VWF propeptide (VWFpp)
Hachulla E. - Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants
Hack E. - Epidermiology and anti-inflammatory mechanism - Latest insight in anti-inflammatory mechanisms
Hack C. E. - Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia
  - Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
  - Alterations in lipoprotein homeostasis during experimental and clinical sepsis in primates
  - Recombinant truncated tissue factor triggers coagulation in normal human plasma via the extrinsic pathway
Hamulyák K. - Functional impairment of protein S in carriers of the prothrombin G20210A mutation
Hackeng T. M. - Function of calcium-dependent protein kinase C in platelet aggregation and thrombus formation: Studies using a chemically synthesized TAT-linked peptide blocking the C2 domain of protein kinase C-beta
  - The regulation of thrombin formation by protein S in plasma in the absence of APC
Hacker C. - Fibrinogen – a new tool for gene delivery
Hadfield A. L. - Does thromboelastography demonstrate hypercoagulability in patients with both a clinical history of thrombosis and the lupus anti-coagulant antibody?
Hadzi-Pecova L. H. - Acquired postpartum hemophilia: report of a case
Haeberli A. - Nonmechanical intraoperative bleeding diathesis shows properties of a consumptive disorder allowing preoperative risk stratification
  - Development of a biosensor system for self-testing the intensity of anti-coagulation by anti-coagulated patients in capillary whole blood
Haemophilia Surveillance System and Project Investigator‡  - Heart disease among males with hemophilia
Haertel S. - Treatment of patients with VWD requiring elective surgery with a pasteurized von Willebrand Factor/FVIII concentrate (Haemate®P) – the use of a PK-guided approach
Hagedorn A. - Prophylaxis of recurrent thromboembolism in a patient with a history of heparin-induced thrombocytopenia with thrombosis, anti-lepirudin antibodies after Bjork-Shiley aortic valve implantation using fondaparinux
Hagelberg S. - Application of a novel polypeptide affinity ligand for purification of recombinant FVIII
Hagemeyer C. E. - Construction and characterization of a new recombinant plasminogen activator composed of an antifibrin single-chain antibody and a low molecular weight form single-chain urokinase
Haim N. - Mechanisms for acquired activated Protein C resistance in cancer patients
Hajime T. - ADP regulates the expressions of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1(PAI-1) in rat aortic endothelial cells
Hakamata Y. - Neonatal injection of human factor VIII induces immune tolerance in murine hemophilia A
Halangoda A. - Hemophilia as a model for analysis of human germ-line mutagenesis: frequent mosacism and low male to female sex ratio for G:C®A:T nonCpG transitions and the first observation of a nucleotide bi-mutation are consistent with effects in early embryogenesis
Haley S. - Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)
Hall S. W. - Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate
Hall L. - The molecular background to von Willebrand disease type 1 in Sweden
Hall M. R. - Reducing body iron stores lowers inflammatory cytokine levels in atherosclerotic claudicants
Hallden C. - The molecular background to von Willebrand disease type 1 in Sweden
Hallqvist J. - The t-PA/PAI-1 complex in plasma in relation to risk of myocardial infarction as evaluated in the Stockholm heart epidemiological program (SHEEP)
  - Prospective evaluation of t-PA/PAI-1 complex predicting myocardial infarction in controls included in the SHEEP study
Halperin J. - Delivering the promise of oral direct thrombin inhibitor therapy to medical practice
Hamacher J. - Duplex screening for quality assurance of postoperative thromboembolism prophylaxis in neurosurgery – Krefeld Study ‘Thrombo 2000’
Hamada M. - Blood coagulation during mural throbogenesis under whole blood flow conditions with high shear rates
  - Mural thrombus generation in classic hemophilia under whole blood flow conditions
Hamaguchi Y. H. - Usefulness of fully automated measurement of reticulated platelet using the whole blood
Hambleton J. - Influence of thrombophilia on efficacy of warfarin for prevention of recurrent venous thromboembolism: results from a randomized trial
Hamill J. D. - Molecular dissection of the human TAFI promoter
Hamilton D. P. - An assessment of the appropriateness of published pediatric dosage guidelines for low molecular weight heparin (Enoxaparin) in a tertiary care institution
Hamm H. E. - Differences in protease activated receptor-1 stimulation between vWF and P-selectin release in endothelial cells-implications of distinct signaling of Weibel–Palade release
Hammes H. P. - Regulation of neovascularization by a-defensins: a link between inflammation and angiogenesis
Hammes M. - Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study
Hammouda W. - Precision of the PFA-100 platelet function analyzer: A practical and cost effective method of quality control (QC) for the clinical coagulation laboratory
  - Determination of the interassay variability of d-Dimer measurements near the critical cut-off point used for the exclusion of venous thromboembolism, on the MDA-180 coagulation analyzer
Hamon Y. - The role of the ATP-Binding Cassette transporter A1 (ABCA1) in phosphatidylserine cell surface exposure and in the modulation of the procoagulant phenotype
Hamptom K. K. - Characterization of mutations in a cohort of type 2 von Willebrand disease patients
Hampton K. - The use of two plasma derived Factor VIII concentrates in type 2 A von Willebrand's disease (VWD)
Hampton K. - Risk factors for carotid artery plaque formation in premenopausal women with systemic lupus erythematosus
Hampton K. - Isolated sustained elevated antib2 Glycoprotein 1 antibodies: association with primary anti-phospholipid syndrome and thrombotic events
  - The relationship between risk factors for premature vascular disease in systemic lupus erythematosis (SLE) with secondary anti-phospholipid syndrome (APS)
Hampton K. K. - The measurement and prevalence of antibodies to prothrombin in patients screened for anti-phospholipid syndrome
  - A novel R2464C candidate von Willebrand factor mutation in families with von Willebrand disease
  - ROTEG thromboelastography: sample stability and results in warfarinized and heparinized patients
Hamsten A. - A relationship between SHBG and APCr during OC treatment
  - Polymorphisms in the thrombomodulin gene as risk factors for myocardial infarction (HIFMECH study)
Hamulyak K. - Screening for annexin A5 gene mutations and the risk of the C-1T mutation in venous thrombosis and myocardial infarction
  - Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Preliminary results of a family cohort study
  - Risk assessment of venous thromboembolism in pregnant women with factor V Leiden, prothrombin 20210 A mutation, elevated factor VIII levels or mild hyperhomocystinaemia
Hamulyák K. - Local changes in coagulation and fibrinolysis in patients with a previous deep venous thrombosis
Hamulyak K. - Increased risk for venous thromboembolism and myocardial infarction in family members of patients with prothrombin 20210 A mutation
  - Venous and arterial thromboembolic risk in first degree family members of patients with elevated plasma levels of clotting factor VIII:c
  - The risk of pregnancy complications in women from families with thrombophilic defects
Tans G. - Functional impairment of protein S in carriers of the prothrombin G20210A mutation
Hamulyak K. - Absolute risk of venous thromboembolism (VTE) associated with a single or combined thrombophilic disorder. Preliminary results of a family cohort study
Hamuro T. - Oxidation products of common phospholipid specifically impair the activity and the reactivity of tissue factor pathway inhibitor
Hamuro T. - Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis
Han J. Z. - Determinations of plasma protein C activity and antigen levels in patients with liver diseases and its clinical significance
Han J. Y. - Characterization of mutations of the factor VIII gene in Korean hemophilia A patients
Han Y. - A novel recombinant factor VIII produced by a human cell line functionally restores coagulation deficits in a mouse model of hemophilia A
Han Y. - A novel point mutation in the transmembrane domain of the platelet glycoprotein IX associated with bernard–soulier syndrome
Han K. P. - Protection of a chimeric antihuman tissue factor monoclonal antibody against tissue factor-induced acute thrombosis in mice
Hanada T. - VWF/FVIII concentrate enhances platelet adhesion onto a surface of immobilized collagen under flow conditions
Hanatani A. - Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II
Handa S. - Dissolving effects of anti-GP IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions
  - Imaging and characterization of the procoagulant activity appeared on the surface of platelet thrombi formed on the collagen surface under blood flow conditions
  - Real-time visualization of platelet shape changes occurring in response to their adhesion on immobilized type I collagen or von willebrand factor under controlled blood flow conditions
  - Platelet GP VI can be new anti-platelet target for prevention of acute coronary syndrome
Handler S. - The impact of interassay-variations in the International Normalized Ratio on dosing oral anti-coagulants
Hanesaka Y. - Activated factor VII enhances whole blood fibrinolysis due to urokinase-type plasminogen activator
Hanfland P. - Treatment of thrombotic complications and prophylactic use of protein C concentrate in two homozygous protein C deficient patients during surgery
  - The risk of heparin-induced thrombocytopenia and the frequency of heparin-dependent antibodies in neurologic patients treated with unfractionated heparin
Hanin I. - Heparin derived oligosaccharides are capable of passing through the blood brain barrier: experimental evidence in a rat model
Hanker-Dusel C. - The thrombogenic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause
Hankey G. J. - Anti-phospholipid antibodies in ischemic stroke
Hanley J. - Factor X Cardiff and Factor X Newcastle: Two new FX mutations associated with low activity and antigen levels
Hann A. H. - Studies to define the clinical impact of ‘mild’ hemophilia A in a large kindred in Newfoundland and Labrador
Hann I. - Transient lupus anti-coagulant directed against factor II
Hanna S. - Levels of D-dimer do not predict deep venous thrombosis in medical–surgical ICU patients
Hannach B. - Extension of human platelet storage up to 7–8 days does not reduce their in vivo viability in a rabbit model
Hansen J. B. - Interactions between tissue factor pathway inhibitor (TFPI) and lipoprotein lipase (LPL) in metabolism of very low density lipoproteins (VLDL)
Hansen H. R. - Rapid arterial thrombus formation after endothelial injury in streptozotocin-induced diabetic mice
Hansen J. B. - Inflammation and endothelial dysfunction in patients with carotid stenosis
Hanson S. - Dose-dependent inhibition of thrombosis by melagatran in a nonhuman primate model
Hanson S. R. - Factor XI dependency of tissue factor-initiated thrombus propagation
Hanson S. - Quantification, as well as functional and phenotypic characterization, of baboon platelet- and plasma-derived factor V demonstrate near identity with human factor V pools
Hanson S. R. - Inhibition of tissue factor initiated thrombosis in vivo
  - CTRP1 – a vascular wall protein that can prevent platelet thrombosis without causing bleeding
Hanson S. - Experience of using FEIBA™ to attenuate the effects of anticoagulation on inhibition of thrombogenesis in primates
Hanss M. - Two electrophoretic fibrinogen variants found in patients with normal coagulation and familial thrombosis
Hanss M. - Comparison of Clauss fibrinogen and fibrinogen measurement derived from aPTT and PT in diabetes mellitus and correlations with markers of glycemic equilibration
Hansson M. - Plasma levels of soluble thrombomodulin and plasma thrombomodulin cofactor activity in the thrombin mediated activation of protein C: a comparative study
Hantgan R. R. - Integrin clustering mechanisms explored with a soluble aIIbb3 ectodomain construct
  - aIIbb3 integrin activation mechanisms – switchblade or scissors?
  - Orally active integrin antagonists perturb aIIbb3 integrin conformation
Hao P. - A chimeric anti-human tissue factor antibody attenuates inflammatory responses in rhesus monkeys challenged with E. coli
Happach C. - Coagulation factor V Leiden not increased in pregnancies complicated by abruptio placentae
Harada N. - Stimulation by antithrombin of sensory nerve-mediated anti-inflammatory pathway in rats
Harada T. - Non-lysine-analog plasminogen modulators: promotion of autocatalytic generation of plasmin(ogen) fragments with angiostatin-like activity and inhibition of tumor growth in vivo
Harada N. - Antithrombin suppresses endotoxin-induced hypotension through the effect of calcitonin gene-related peptide
Haramura G. - Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding
  - Activation of factor XIII in whole plasma: the influence of Val34Leu polymorphism
  - Factor XIII subunit B: a protein A binding protein
Harbrecht U. - The risk of heparin-induced thrombocytopenia and the frequency of heparin-dependent antibodies in neurologic patients treated with unfractionated heparin
Harder S. - How to switch from thrombin inhibitors to oral anticoagulants
  - Influence of argatroban alone and combined with oral anticoagulants on the assessment of coagulation factors
Harder S. - Effects of argatroban alone or in combination with phenprocoumon or acenocoumarol on aPTT and ecarin clotting time
  - Effects of argatroban in combination with oral anticoagulation on thrombin generation
  - Transition of treatment with i.v. Argatroban to Phenprocoumon and Acencoumarol
Hardingham S. - The suitability of various evacuated blood collection tubes for monitoring heparin
  - A comparison of various evacuated blood collection tubes for monitoring warfarin therapy with Innovin
  - Comparison of normal values for coagulation measurements in a variety of evacuated containers
Hardy A. - P2Y1 signaling through Src tyrosine kinase in human platelets
Harenberg J. - Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
  - Relation of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis with the low molecular weight heparin Certoparin or unfractionated heparin
  - Inhibition of blood coagulation by ximelagatran in patients with a first episode of symptomatic acute deep venous thrombosis for prophylaxis of recurrent events
  - Treatment of patients with a history of heparin-induced thrombocytopenia (HIT type II) and of anti-lepirudin antibodies with argatroban or lepirudin
Harenberg J. - Anti-coagulant effects of direct thrombin inhibitors: compared for potential use in clinical practice
  - International collaborative study on analyzing methods for determination of direct thrombin inhibitors
Harenberg J. - Prophylaxis of recurrent thromboembolism in a patient with a history of heparin-induced thrombocytopenia with thrombosis, anti-lepirudin antibodies after Bjork-Shiley aortic valve implantation using fondaparinux
Harenberg J. - Impact of direct thrombin inhibitors on actions of vitamin K antagonists on analysis with different coagulation parameters: aPTT and PT for argatroban, hirudin and melagatran
Häring D. - Variation in plasminogen activator inhibitor-1 gene and risk of meningococcal disease
Harlé J. R. - Activation of p38 MAPK promotes an endothelial adhesive phenotype in response to anti-phospholipid antibodies
Harmer I. J. - Human glycoprotein VI: identification and blockade of the collagen-binding surface
  - Platelet glycoprotein VI has evolutionary conserved immunoglobulin domains, but a highly polymorphic stem and cytoplasmic domain
Harmer I. - Loss of tolerance for platelet glycoprotein VI by vaccination of Balb/c mice with a GPVI-tetanus toxoid fusion protein
Harms D. - Disseminated intravascular coagulation after varicella infection
Harper P. - Protein Z-dependent protease inhibitor (ZPI) deficiency: a new thrombotic risk factor?
Harper P. L. - Warfarin loading with a 5-mg daily dose for the first 3 days of treatment is safe and effective for the management of patients with venous thrombosis
Harper P. - Correction of coagulation, as measured by the thromboelastogram, with low dose recombinant VIIa treatment in a patient with a factor VIII inhibitor
Harper P. - The rate of thrombus resolution following treatment of DVT is related to the site and the precipitating cause of thrombosis
Harrington D. - Multivariate investigation of determinants of oral anti-coagulant stability
Harrington R. A. - Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
Harrington A. - Xa Neutralization for Atherosclerotic Disease Understanding
Harrington D. G. - Increased platelet activation in hyperhomocysteinemic patients
Harris E. N. - Inhibitors of NFkB and p38 kinase abrogate tissue factor up-regulation by anti-phospholipid antibodies
Harris V. K. - Geographic distribution of asymptomatic constitutional macro thrombocytopenia in Indian subcontinent
Harris E. N. - Intracellular events in antiphospholipid-mediated platelet activation
  - Effects of fluvastatin on up-regulation of tissue factor by antiphospholipid antibodies
Harris S. L. - Preparations of beta-2 glycoprotein I contain plasma kallikrein
Harrison P. - The interaction of von Willebrand factor with GPIba; induces GPIIb-IIIa-dependent secretion
  - The PFA-100®: a screening tool for platelet dysfunction – the Oxford experience
Harrison S. J. - Evaluation of the role of genetic analysis in dysfibrinogenemia
Harrison J. - Pharmacokinetics of functional von Willebrand Factor (VWF) with infusion of Koate-DVI® in patients with von Willebrand's Disease (VWD)
Harrison P. - Variation of GPVI levels in platelets: relationship to platelet function at high shear
Harrison T. - Structure of the Glycoprotein Ib N-terminal domain
Harrison P. - Expression of prion protein (PrPC) in the megakaryocyte lineage
  - The mechanism of platelet activation by recombinant factor VIIa in normal subjects and inherited hemostatic disorders – a whole blood, flow cytometric study
  - Markers of hemostatic activation and protein Z in acute stroke and myocardial infarction: a community based pilot study
  - ‘Aspirin resistance’ detected by high shear platelet function testing within the pilot phase of the Oxford Vascular Study (OXVASC)
Harroff H. H. - Elevated coagulation factors in rabbits (Oryctolagus cunniculus) following brown recluse envenomation (Loxoceles reclusa)
Harsanyi A. - Thrombolytic therapy in acute ischemic stroke: same method, same team, different drug
Harsfalvi J. - GPRP interferes with FXIIIa in localization to immobilized Fibrin(ogen) and with platelet deposition in different thrombosis models
Hartmann W. - Expression and function of platelet glycoproteins in newborns and adults
Hartmann L. - Different thromboprophylaxis approaches in patients undergoing knee arthroscopy (KANT study): interim report of prospective randomized study
Hartwich J. - Sialic acid and lipid contents of low density lipoprotein in relation to platelet receptor activity
Hartwig C. - Altered vascular remodeling in hyperfibrinogenemic mice
Hartwig J. - Birth of the platelet
Haruhiko K. - Effect of anti-coagulant and anti-platelet agents on LPS-induced alteration of whole blood fluidity
Haruta S. - The functional profiles of circulating T lymphocytes distinguishes patients with stable angina and unstable angina
Harvald T. - Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after major abdominal surgery: the FAME study
Harvey E. J. - Haematologic factors potentially implicated in the pathophysiology of avascular necrosis of the femoral head (AVN): hypercoagulability as a cause of AVN
Hasegawa H. - Different distribution of antithrombin and thrombomodulin in endotoxin-treated rat: effect of antithrombin and activated protein c concentrates and nafamostat mesilate
Hasegawa M. H. - Recombinant sendai virus-mediated intramuscular gene transfer of FGF-2 restores collateral blood perfusion of chronically ischemic rabbit hind limb, and inhibits neointimal hyperplasia of autologous femoral vein grafts
Hasegawa M. - Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747, a novel P2Y12 receptor antagonist
Haselbeck M. - Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception
Hashemi M. - Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
Hashemi S. M. B. - Fluorescent conformation sensitive gel electrophoresis (F-CSGE) analysis of the VWF gene: A high throughput, sensitive mutation detection system
Hashiguchi T. - Activated protein C as a proteolytically activable antioxidant, anticoagulant protein
Hashimoto M. - Effect of ADP P2Y12 receptor inhibition on thrombosis and bleeding measured using guinea pigs
Hashimoto M. - GTT: A comprehensive in vitro haemostasis test, assessing platelet function, coagulation and thrombolytic activity from a single native blood sample
Haspekova S. G. - Using NovoSeven (NS) – recombinant factor VIIa to control the bleedings in Bernard-Soulier (BSS) girl. Case report
Hass M.J. - Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes
Hasselblad V. - Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
Hassell K. - Unexpected pattern of hypercoagulable states in patients with patent foramen ovale (PFO) or atrial septal defect (ASD) and neurological events
Hassenpflug W. - Use of recombinant factor VIIa in severe acquired coagulopathies in childhood
Hasslacher M. - Surface exposed mutation W2313A in the C2-domain of FVIII results in defective secretion of otherwise functional protein
Hassock S. R. - PIP3 induces human platelet aggregation via an activation of a nonselective cation entry channel
Hasstedt S. J. - Heritability of clotting factors and the prothrombotic state: results from a large thrombophilic pedigree of French Canadian descent with Type I protein C deficiency
Hasumi K. - Affinity-trap protease reactor for single-step conversion/purification of angiostatin from human plasma
  - Non-lysine-analog plasminogen modulators: promotion of autocatalytic generation of plasmin(ogen) fragments with angiostatin-like activity and inhibition of tumor growth in vivo
Hatake K. - The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors
Hatakeyama K. - Localization and activity of ecto-ATP diphosphohydrolase/CD39 in human tissues
  - Coagulation system and inflammation significantly contribute to thrombus formation in ruptured plaques than erosive plaques of acute myocardial infarction
  - Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis
Hathaway L. - The efficacy of standard dose vs. 30 mL kg-1 FFP in correcting laboratory parameters of hemostasis in critically ill patients
Hathcock J. - Vascular biology - the role of tissue factor
Hatron P.Y. - Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants
Hatton M. - Fibrinolysis within the procoagulant VX-2 tumor of rabbit lungs in vivo: Anti-angiogenic behavior of fibrin(ogen) degradation products
Hatzitolios A. - Acute ischemic strokes: LMWHs or aspirin administration and laboratory follow-up
Hatzitolios A. I. - Acute ischemic strokes: LMWHs or aspirin administration and laboratory monitoring
Haulon S. - Tissue factor pathway in carotid atherosclerotic plaques: relationships with clinical patterns and risk factors
Hauser C. - A novel recombinant factor VIII produced by a human cell line functionally restores coagulation deficits in a mouse model of hemophilia A
Hausl C. - Differentiation of factor VIII-specific memory B cells into anti-factor VIII antibody-secreting cells requires direct interaction between memory B cells and activated T cells but is not dependent on factor VIII-specific T cells
Haverkate F. - Harmonization of D-Dimer test results
  - The long-term analytical performance of assay of anti-thrombin, protein C and protein
Havik S. R. - Generation and characterization of a highly stable form of activated TAFI
Hawe E. - Polymorphisms in the thrombomodulin gene as risk factors for myocardial infarction (HIFMECH study)
Hay C. R. M. - Automated DNA sequencing of the essential regions of the FVIII gene for rapid carrier and prenatal diagnosis in hemophilia A
  - Type 2M von Willebrand disease: correlation of phenotype with genotype?
Hay C. - Inhibitors and their management using immune tolerance induction therapy
  - Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs)
Haya S. - Detection the 3614 G > A (R1205H) mutation in the VWF gene in 26 Spanish patients with high penetrance dominant type 1 von Willebrand disease
  - Treatment with recombinant activated factor VII of intra-abdominal bleeding associated with disseminated intravascular coagulation caused by septic shock
Hayashi T. - Activation of a novel 33-kDa SER/THR kinase by tyrosine kinase and calpain in thrombin-stimulated platelets
Hayashi M. - Ryudocan (syndecan-4) deficiency increases susceptibility to LPS-induced shock in mice
Hayashi T. - C-reactive protein induces the expression of tissue factor and interleukin-8 in the lung
Hayashi T. - Decreased expression of protein C inhibitor in renal cell carcinoma cells is partly caused by DNA methylation
Hayes P. D. - The anti-platelet effect of aspirin is reduced following administration of heparin during carotid endarterectomy
  - Prevention of thromboemboli by enhancing fibrinolysis: a possible therapeutic mechanism of action for Dextran-40
Hayes T. - APTT Clot Waveform Analysis in Patients Presenting with Sepsis to the Emergency Department
Hayes J. P. L. A. - Identification of a family with discrepant von Willebrand factor collagen binding assays (VWF:CB)
Hayes T. E. - APTT transmittance waveform analysis in a cohort of septic patients
Hayes V. W. - Reducing body iron stores lowers inflammatory cytokine levels in atherosclerotic claudicants
Hayoz D. - Diagnosing pulmonary embolism with clinical assessment, d-dimer, venous ultrasound and helical computed tomography: a multicenter management study
Hayward C. P. M. - Identification of the multimerin binding region within the C2 domain of human factor V using constructs generated by alanine scanning and site-directed mutagenesis
  - Platelet-dependent alterations in fibrinolysis in the Quebec platelet disorder
  - Multimerin supports platelet adhesion by functioning as an RGD ligand for platelet integrin receptors
  - Variability of clinical laboratory practice in testing for disorders of platelet function: results of a NASCOLA survey
He X. F. - Influence of tetramethylpyrazine on the expression of tissue factor induced by proinflammatory cytokines in endothelial cells
He S. L. - Influence of tetramethylpyrazine on the expression of tissue factor induced by proinflammatory cytokines in endothelial cells
He S. L. - Effect of angiotensin II on tissue factor expression in human peripheral blood monocytes
He M. X. - Effect of angiotensin II on tissue factor expression in human peripheral blood monocytes
He X. F. - Effect of angiotensin II on tissue factor expression in human peripheral blood monocytes
He M. X. - Mechanisms for angiotensin II on tissue factor expression in human peripheral blood monocytes
He X. F. - Mechanisms for angiotensin II on tissue factor expression in human peripheral blood monocytes
He S. L. - Mechanisms for angiotensin II on tissue factor expression in human peripheral blood monocytes
He X. F. - Effects of adrenaline and noradrenaline on the expression of tissue factor in endothelial cells
He S. L. - Effects of adrenaline and noradrenaline on the expression of tissue factor in endothelial cells
He J. - Use of umbilical cord vein in an in vitro perfusion model to study blood-borne metastasis
He S. - Determination of overall hemostasis potential in different coagulation factors deficient plasma and in plasma samples from patients with hemophilia A and B
He S. - Improvements in flow measurements of fibrin network permeation in plasma or purified fibrinogen-thrombin system
He X. F. - Determinations of plasma protein C activity and antigen levels in patients with liver diseases and its clinical significance
He S. L. - Determinations of plasma protein C activity and antigen levels in patients with liver diseases and its clinical significance
Head S. - Platelet integrin a2 SNP 807C is a predictor of bleeding in Von Willebrand Disease (VWD) type 1
Head M. W. - Variant Creutzfeldt–Jakob disease and its transmission by blood
Healey J. F. - Determination of free sulfhydryls in human factor VIII
  - Characterization of high level expression sequence determinants within porcine factor VIII
Heath A. B. - Variability in factor VIII concentrate measurement: results from SSC Field Collaborative Studies
Heatherly D. P. - Release of chemokines by monocytes and endothelial cells upon exposure to Shiga toxin and LPS: potential roles in platelet activation
Hebbel R.P. - Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes
Hechler B. - Activation of RhoA and Rac through Gq- and G12/G13-mediated pathways in mouse and human platelets stimulated by TXA2 or ADP
Hechler B. - A key role of the fast ATP-gated P2 X 1 cation channel in the thrombosis of small arteries in vivo
Hechler B. - The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser-induced model of arterial thrombosis in vivo
Hechler B. - A key role of the fast ATP-gated P2X1 cation channel in the thrombosis of small arteries in vivo
Hedden D. - Final results from the Canadian hemophilia dose escalation prophylaxis trial
Hedin U. - Influence of intraluminal thrombus on cellular and structural features of the aneurysm wall
Hedner U. - In vivo monitoring of hemophilia A patients with inhibitors under recombinant factor VIIa therapy
  - Pharmacokinetics, pharmacodynamics and tolerability of single injections of activated recombinant FVII (rFVIIa, NovoSeven®) in healthy Caucasian and Japanese subjects
  - Dosing with rFVlla - based on current evidence
Heeb M. J. - Downregulation of Factor IXa in the Factor Xase complex by protein Z-dependent protease inhibitor (ZPI)
Heeg S. - cGMP regulates thrombopoietin-induced CD34+ human stem cell proliferation and differentiation into megakaryocytes
Heegaard C. W. - Limited exposure of phosphatidylserine on stimulated platelets is necessary for procoagulant activity and provides binding sites for lactadherin
  - Anticoagulant function of lactadherin correlates with phosphatidyl-L-serine specificity
Heemskerk J. W. M. - Effects of platelet agonists and antiplatelet agents on thrombin formation in human plasma
Heemskerk J. - Binding of minute amounts of thrombin to GPIbalpha accelerates early platelet reactions, but not the platelet procoagulant response
Heemskerk J. W. M. - In vivo involvement of ADP in thromboembolism through its receptors P2Y1 and P2Y12
  - Role of PI 3-kinase in glycoprotein VI-dependent calcium signaling in human platelets
Heemskerk J. M. W. - A new platelet activation marker specific for activated integrin alpha2beta1: monoclonal antibody IAC-1
Heemskerk J. W. M. - Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype
Heemskerk J. - Function of calcium-dependent protein kinase C in platelet aggregation and thrombus formation: Studies using a chemically synthesized TAT-linked peptide blocking the C2 domain of protein kinase C-beta
Heemskerk J. W. M. - Interplay of glycoprotein Iba, integrin a2b1 and glycoprotein VI is required for human thrombus formation under flow
  - Storage of apheresis platelets leads to reduced adhesiveness and thrombogenic activity in flowing whole blood ex vivo
  - Integrin activation upon human platelet adhesion to collagen under flow
  - Effects of dietary fish oil on coagulation and platelets
  - Glycoprotein Ib and integrin a IIbb 3 contribute to GPVI-dependent vWF-collagen induced thrombus formation under flow
Heemskerk J. W. - Regulation of platelet procoagulant activity by collagen
Heffernan J. - Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition
Hegadorn C. A. - The type 1/type 2M von Willebrand disease dilemma: findings from the Canadian Type 1 VWD study
  - Clear familial co-segregation of the type 1 von Willebrand disease phenotype and VWF haplotypes in the Canadian type 1 VWD study
Hegadorn C. - An ancient von Willebrand Disease (VWD) mutation that associates with a common haplotype in ~14% of type 1 VWD patients
Heiden M. - Coagulation factor V in normal bronchial epithelial and lung cancer cells
Heider A. - Determination of direct thrombin inhibitors like hirudin in plasma – Comparison of the Ecarin Chromogenic Assay (ECA) with the Ecarin Clotting Time (ECT) and the Activated Partial Thromboplastin Time (APTT)
Heijboer H. - The clinical outcome of pediatric venous thrombo-embolic disease in one tertiary centre
Heijnen L. - An evaluation of 30 years of hemophilia treatment in the Netherlands
Heijnen H. F. G. - Co-localization of c-AMP-dependent PKA with eNOS in endothelial cell junctions: a clue for regulated NO production
Heijnen H. F. G. - Cholesterol-microdomains in platelet adhesion and aggregation
Heijnen L. - Mortality of Dutch hemophilia patients, a prospective follow-up of 973 patients, 1992–2002
Heilmann J.-J. - A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of Tinzaparin and Enoxaparin given at prophylactic dose over 8 days in elderly patients with impaired renal function
Heim D. - VCAM-1/VLA-4 up-regulation as a perpetuation loop in patients with chronic graft vs. host disease?
Heim V. - A key role of the fast ATP-gated P2 X 1 cation channel in the thrombosis of small arteries in vivo
  - A key role of the fast ATP-gated P2X1 cation channel in the thrombosis of small arteries in vivo
Heinonen K. - Development of hemostasis in the very low birth weight premature infants
Heinrichs C. - The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A
Heinz S. - Intracellular trafficking of native, full-length, and B-domain-deleted coagulation factor VIII (FVIII) in mammalian cells
Heit J. A. - Genetic susceptibility of venous thromboembolism: role of the procoagulant, anticoagulant, fibrinolytic, and acute inflammation pathways
Heit J. A. - Treatment and management of women with bleeding disorders and menorrhagia (WBDM) study: study design and characteristics of women enrolled
Hellegren M. - Excretion of the oral direct thrombin inhibitor ximelagatran into breast milk following oral administration to breast-feeding women
Heller C. H. - Elevated factor VIIIC and further prothrombotic risk factors in paediatric venous thrombosis and stroke: a multivariate analysis
  - Sinus venous thrombosis in children – a multifactorial etiology
Heller C. - Clinical manifestation and therapy in children with hereditary angioedema (HAE) – a prospective follow up
  - F VIII:C, Ristocetin-cofactor and von Willebrand factor in children with venous thrombosis or cerebral infarction
  - Factor XII-deficiency is a risk factor for ischaemic stroke but not for venous thrombosis in children
Helley D. - A new co-operative effect of low molecular weight polysaccharides and cell surface heparin sulfate in enhancing bFGF-induced endothelial cell differentiation
Hellmig S. - Influence of anti-thrombin on platelet adhesion onto immobilized fibrinogen in simulated low flow in vitro system
Hellot M.-F. - Prethrombotic biological markers in congenital thrombophilic patients. Preliminary results of a randomized long-term secondary prophylaxis study using warfarin and comparing two INR target ranges
Hellwege H. H. - Use of recombinant factor VIIa in severe acquired coagulopathies in childhood
Helmerhorst F. M. - Procoagulant factors and the risk of myocardial infraction in young women
  - Estrogens, progestogens and thrombosis
Helmy A. - Interrelation between light and ultrastructure study of bone marrow in thrombocytopenic patients with chronic liver diseases: morphological changes and factors affecting thrombopoiesis
Helmy A. - Ultrastructural changes in platelets after surgical manipulations in pigs liver
Helvig B. - Cross-talk between alpha2beta1 integrin and GPVI receptors regulates actin polymerization through Rho GTPase and MAP kinase Erk1/2 signaling pathways in human megakaryocytes
Hemker H. C. - Exposure of procoagulant phospholipids in blood during exhaustive physical exercise
  - Effects of platelet agonists and antiplatelet agents on thrombin formation in human plasma
  - Defective vWF–Fibrin–GPIb interaction causes impaired prothrombin consumption in Bernard–Soulier Syndrome
  - Thrombinography can differentiate bleeding from nonbleeding patients with prolonged APTT
  - The calibrated Thrombogram: exact monitoring of thrombin generation in clotting platelet rich- and platelet poor plasma
  - Patients with mild hereditary bleeding disorders have normal thrombin generation (TGPPP) in platelet poor plasma
Hemker H. C. - Prolongation of the aPTT is far inferior to thrombin generation as an indicator of the heparin anti-coagulant effect
Hemker H. C. - Increased thrombin potential due to acquired activated protein C resistance in patients with lupus anticoagulants
Hemophilia Surveillance System & Project Investigators‡  - Renal disease among persons with hemophilia
Hemo-Qol Investigators Group‡  - Validation of the first hemophilia-specific quality of life questionnaire for children and adolescents (Hemo-QoL)
Henckel T. - Frozen or lyophilized normal plasmas pose a strong bias for reporting PT values
Henckel T. - Performance of a new PT Calibrator
Henderson D. J. - Thromboembolism in childhood: a prospective 2 years study in the United Kingdom (February 2001 – February 2003)
Hendler M. F. - Low molecular weight heparin (LMWH) in pregnant women with mechanical prosthetic heart valves (MPHV)
Hendler M. - Anticoagulation therapy outcome in children after extracardiac conduit Fontan operation
Hendrickson S. B. - Altered vascular remodeling in hyperfibrinogenemic mice
Hendriks D. - Carboxypeptidase U (TAFIa) prevents fibrinolysis from proceeding into the propagation phase through a threshold-dependent mechanism
Hendriks-Linders Y. E. M. - Two sensitive chromogenic assays of fondaparinux sodium (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in plasma
Hene R. - The sensitivity and specificity of ADAMTS13 activity for primary thrombotic thrombocytopenic purpura
Henlin J. M. - Influence of selective nonpeptide PAR-1 and PAR-4 antagonists on thrombin-induced aggregation of human platelets
Henni T. - Successful use of rFVII for an hemorrhagic Port-a-cath insertion in a Fanconi's disease
Henny CH. P. - Day-care or short-stay surgery and venous thromboemolism: an overview
Henriques I. - Association of MTHFR and ACE gene polymorphisms in reflux associated with renal damage
  - A different view on the inflammatory bowel disease – the role of adhesion molecules and angiogenic growth factors
Henschen A. - Anti-fibrinogen IgG from a thrombophilic A alpha R16C (Fibrinogen Northspring) proband accelerates release of clot bound thrombin by enhancing fibrinolysis: a novel thrombogenic mechanism
Hense M. - Evaluation of a ‘handheld’ communicator based electronic system for documentation of hemophilia A and B therapy in home-care settings
Hentig N. V. - Transition of treatment with i.v. Argatroban to Phenprocoumon and Acencoumarol
Henze W. - Stability of rFVIII-FS after continuous infusion using a mini-pump infusion device
Hepner M. - Venous thromboembolism (VTE) in children: A prospective 10-year registry in Argentina
  - Biological and clinical DDAVP response in children with von Willebrand disease (VWD)
  - Cerebral sinovenous thrombosis (SVT) in children: a prospective 10-year registry in Argentina
  - Arterial ischemic stroke (AIS) in children: a prospective 10-year registry in Argentina
Heptinstall S. - The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke
  - Effects of ADP-antagonists on platelet calcium mobilization in acute coronary syndrome patients
  - P2Y12 antagonists interact with agents that stimulate adenylate cyclase to inhibit calcium mobilization responses in platelets
  - Thromboxane A2 is a weak platelet agonist requiring coactivation of both the P2Y1 and the P2Y12 receptors for full platelet activation to occur
  - Activated platelets and platelet-derived microvesicles (PMV) transfer tissue factor (TF) to monocytes but not to neutrophils
Heptinstall S. - The mechanism of platelet aggregation in whole blood in response to adenosine triphosphate: involvement of neutrophil ecto-ATPase activity and adenosine
Heptinstall S. - Platelet–leukocyte interactions in the presence of GPIIb-IIIa antagonists, and a combination of aspirin, dipyridamole and AR-C69931
Herández A. - Transmission electron microscopy of granulocyte inclusions in genetically confirmed MYH9-related disorders
Herault J.-P. - Antithrombin-mediated inhibition of factor IXa by synthetic oligosaccharides
  - Effect of anticoagulants with various modes of action on thrombin generation in plasma of mice with targeted Arg47-to-Cys mutation of the heparin-binding domain of antithrombin
Herbert J.M. - Effect of anticoagulants with various modes of action on thrombin generation in plasma of mice with targeted Arg47-to-Cys mutation of the heparin-binding domain of antithrombin
Herbert J.-M - Antithrombin-mediated inhibition of factor IXa by synthetic oligosaccharides
Herbert J. M. - Thrombolysis induced by streptokinase or recombinant plasminogen activator (rt-PA) is improved by SSR182289A, a direct orally active thrombin inhibitor, in rabbit models of thrombosis
  - Deficiency in one Gas6 receptor (Axl, Sky or Mer) protects mice against thrombosis because of a platelet dysfunction
Herbertson M. - Residual platelet function can be detected in patients on antiplatelet therapy using novel Hemoscope reagents and standard Thrombelastograph® (TEG®)
Herbiniaux U. - Analysis of mRNA in a panel of hemophilia A patients with no detectable mutation in the coding regions of the factor VIII gene
Herder C. - Developing hematopoietic stem cells as targets for gene therapy of hemophilia A
Hermansson K. - Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement
  - The effect of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, on the prolongation of aPTT and ECT in orthopedic patients: a population pharmacodynamic study
Hermida J. - Impaired interaction of protein C Gla domain variants with the endothelial cell protein C receptor (EPCR)
Hermiller J. B. - Rapid point-of-care assessment of enoxaparin activity during percutaneous coronary interventions: the ELECT study
Hernandez B. - Lipoprotein (a) polymorphisms in Mexican-Amerindian populations
Hernández M. R. - Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model
Hernandez-Campo P. - Platelet CD109: evidence for a transmembrane homologue on monocytes?
Herrera L. - Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
  - Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
Herrmann F. - Development of inhibitors against factor VII in patient with severe factor VII deficiency
Herrmann F. H. - Molecular genetic analysis of gene variants in the 5' flanking region of the FVII gene: Identification of a novel mutation in a German family
  - Molecular genetic analysis in the factor X gene in patients with congenital FX deficiency
Herrmann M. - The coordinated transcription of genes encoding regulators of cell cycle progression revealed by expression profiling upon calcium ionophore A23187 treatment of B lymphoblasts from a patient with Scott syndrome
Hertfelder H. J. - Treatment of thrombotic complications and prophylactic use of protein C concentrate in two homozygous protein C deficient patients during surgery
Hertzberg M. - Laboratory diagnosis of von Willebrand Disorder: current and past practice in Australasia
Hervig T. - Elevated concentrations of nitrate in plasma from smokers
  - Prevalence of hyperhomocysteinemia among aluminum industry workers
Herzog R. W. - A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
  - Improving efficacy of gene therapy of hemophilia B by the use of mutant FIX variants
Heslop J. - Real-time whole-blood coagulation following ex vivo hemodilution with plasma substitutes: reversal of the coagulopathy by a fibrinogen concentrate
Hess J. - Duplex screening for quality assurance of postoperative thromboembolism prophylaxis in neurosurgery – Krefeld Study ‘Thrombo 2000’
Hetland O. - Tissue factor is a major determinant of thrombogenicity following an acute myocardial infarction
Heuer L. - Why did rFVIIa have no effect in post delivery bleeding? – a case-report
Heul Van Der C. - The assessment of pretest probability in patients with suspected Deep-Vein Thrombosis is of great value in nonacademic teaching hospitals
Heuss D. - Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception
Hevelow M. - Tissue factor in sickle cell disease: Source and potential mediators
Heward J. - High affinity heparin binding proteins are exposed on the surface and microvesicles of TF bearing cells and diminish heparin-mediated anticoagulation
  - Heparin neutralising agents instigate the binding of heparin to live cells
Hewitt J. - Severe factor VII deficiency caused by a new point mutation combined with a previously undetected gene deletion
  - Molecular basis of the bleeding disorder caused by Prothrombin-Vancouver
  - Increase in platelet VEGF release in early breast cancer
Hewlett L. - Analysis of storage and regulated secretion of three human variants of von Willebrand factor provides new insights into von Willebrand's disease
Heyland D. K. - Issues arising in application of the ISTH disseminated intravascular coagulation (DIC) scoring system: the need for modification before prospective validation
Hézard N. - Increasing the dosage of aspirin before percutaneaous coronary intervention: is there any effect in aspirin resistant patients? A randomized study
  - Platelet function peculiarities throughout childhood: a flow cytometric study from healthy premature new-borns up to 15-year-old-children
Hickey M. J. - The cytoplasmic domain of tissue factor plays an important role in innate and adaptive immunity
  - The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia
Hidalgo P. - Lack of association of platelet membrane glycoprotein polymorphisms with the clinical expression of von Willebrand disease type 1
Hidehiko K. - ADP regulates the expressions of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1(PAI-1) in rat aortic endothelial cells
Hiebert L. M. - The effect of orally administered heparins on a rat carotid arterial model of thrombosis
Hiet J. A. - Familial segregation of venous thromboembolism
Higashi T. - Effects of strong static magnetic fields on fibrinolysis
Higashitani M. - The functional profiles of circulating T lymphocytes distinguishes patients with stable angina and unstable angina
High K. A. - Improving efficacy of gene therapy of hemophilia B by the use of mutant FIX variants
High K. A. - A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
Hilbert L. - In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients
  - Identification and expression of the first type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene
  - Type 2N von Willebrand disease due to compound heterozygosity for the frequent R854Q type 2N mutation and a new R763G mutation abolishing the cleavage of von Willebrand factor propeptide
  - Expression of a new candidate mutation, G1629R, identified in an Italian patient with type 2A von Willebrand disease
Hilbert L. - Stability of 19 mutated recombinant von Willebrand factor to von Willebrand factor-cleaving protease (ADAMTS13)
Hild E. - The molecular mechanisms of platelet activation by prolactin
Hildemann S. K. - Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation
Hilgenfeld R. - Mutation profiling in congenital FXIIIA deficiency: detection of 6 novel mutations
Hilkes Y. H. A. - Exposure of a binding site for the low-density lipoprotein receptor-related protein (LRP) upon activation of factor V
Hill F. - Splice site mutations of the von Willebrand factor gene in patients previously diagnosed with von Willebrand disease type 1
  - In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients
  - Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
  - Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
Hill M. - Evaluation of the role of genetic analysis in dysfibrinogenemia
Hill A. - Increased plasma isoprostanes and other markers of oxidative stress in chronic fatigue syndrome
Hill F. G. H. - Two candidate type 2 M von Willebrand disease mutations in two unrelated families with unusual phenotypes
Hill F. - Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD
Hill F. G. H. - Inherited and de novo von Willebrand disease ‘Vicenza’ in UK families with the R1205H mutation
  - A common mutation 4247T ® A (I1416N) causing type 2M von Willebrand disease in patients from three unrelated families previously diagnosed as severe type 1 VWD
Hill F. - An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
Hill F. G. H. - Identification of six novel mutations in families with type 3 von Willebrand disease
  - Evaluation of a protein truncation test (PTT) for mutation detection in von Willebrand disease
Hill F. - Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD)
Hill F. G. H. - Are there really undetectable Factor VIII mutations in hemophilia A? How can we deal with the difficult ones?
  - Identification of factor IX mutations in 17 Iranian families with hemophilia B
  - Compound heterozygous Protein C deficiency resulting in neonatal purpura fulminans: identification of a novel mutation and its functional consequences
Hillarp A. - The molecular background to von Willebrand disease type 1 in Sweden
  - Genetic variation at the human thrombomodulin promoter locus and prognosis after acute coronary syndrome
  - A comparative in vitro evaluation of seven von Willebrand factor concentrates
  - Evaluation of an automated assay for rapid analysis of von Willebrand ristocetin cofactor activity
Hillelson P. - Acute hyperglycemia enhances platelet secretion but not platelet aggregation
  - Platelet function and inflammatory markers in patients with type 1 diabetes with and without microvascular complications
Hillery C. A. - Assay of the von Willebrand factor propeptide in patients with type 1 von Willebrand disease (VWD) and the identification of patients with a S2179F mutation in the D4 region of von Willebrand factor
Hilliard E. - Bleeding phenotype and decreased viability in rap1b knockout mice
Hilliard P. - Final results from the Canadian hemophilia dose escalation prophylaxis trial
Hillman-Wiseman C. - An interactive coagulation laboratory database benefiting the entire Hemophilia Center team
Hillman-Wisman C. - An improved simpler method for using the ReFacto™ Laboratory Standard in monitoring patients receiving BDDrFVIII
Hillmen P. - Platelet CD109: evidence for a transmembrane homologue on monocytes?
Himeno R. - Activation of factor IX by erythrocyte membranes is a trigger for coagulation at stasis
Hinks J. - Fluorescent conformation sensitive gel electrophoresis (F-CSGE) analysis of the VWF gene: A high throughput, sensitive mutation detection system
Hirano M. - Abnormal subcellular localization of neutrophil nonmuscle myosin heavy chain-A (NMMHCA) is associated with MYH9 mutations in patients with autosomal dominant macrothrombocytopenia with leukocyte inclusions
Hirosawa S. - Degradation pathway of the naturally occurring mutants of protein C and plasmin inhibitor by the proteasome
Hirschl M. - Assessing the risk of recurrence in patients with a first spontaneous venous thromboembolism by use of D-dimer
Hirsh J. - Evaluation of a venous-return assist device (venowave) to treat post-thrombotic syndrome: a phase II study
  - A systematic review of venous thromboembolism and long distance travel: strength of association and evidence for prevention
  - Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review
  - Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial
  - GH9001, a novel anti-thrombotic agent, is more effective than low-molecular-weight heparin, fondaparinux, or hirudin in rabbit models
Hisato K. - ADP regulates the expressions of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1(PAI-1) in rat aortic endothelial cells
Hishinuma I. - Anti-thrombotic effects of ER112787, a novel, nonpeptide thrombin receptor (PAR-1) antagonist, in a photochemically induced thrombosis model using guinea pigs
Hitos K. - Venous thromboembolism and fractured neck or femur
Hixson J. - A genome-wide scan for genetic loci influencing levels of thrombin-activatable fibrinolysis inhibitor (TAFI)
Hizroeva D. H. - A case of catastrophic anti-phospholipid syndrome in pregnant woman with eclampsia
Hjemdahl P. - Clopidogrel treatment reduces platelet activity in vivo, but does not counteract exercise-induced platelet activation
Hjemdahl P. - Clopidogrel treatment provides limited protection against exercise-induced platelet-leukocyte conjugation
Hjemdahl P. - Platelet function and inflammatory markers in patients with type 1 diabetes with and without microvascular complications
  - Enhanced platelet and leukocyte activation by strenuous exercise in type I diabetes mellitus
  - Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus
  - Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins
Ho W. - Perioperative management of patients on oral anti-coagulants: a decision-analysis
Ho P. L. - Recombinant Lopap (a prothrombin activator from Lonomia obliqua) has a very conservative structure of lipocalins
Ho L. P. - Thrombotic events associated with the use of recombinant factor VIIa in a single institution: a role for caution
Ho Y. K. L. - Radioisotopic synovectomy and haemophilic arthropathy in Asians: a retrospective study
Ho L. P. - Projection parameters for usage of blood products in Singapore General Hospital
Ho S. H. - An assessment of the appropriateness of published pediatric dosage guidelines for low molecular weight heparin (Enoxaparin) in a tertiary care institution
Ho Tin Noe B. - Pericellular plasmin induces smooth muscle cell anoikis
Hochart H. - NovoSeven does not produce an inflammatory reponse in a monocyte (THP-1) cell line or primary monocytes prestimulated with lipopolysaccharide
  - Thrombin causes an inflammatory cytokine response, which is inhibited by protein C, in both primary human monocytes and a monocyte (THP-1) cell line
Hock Toh C. - Introduction - A Hematologist's Perspective on Sepsis related DIC
Hod H. - Monitoring the combined effect of integrilin, clopidogrel and aspirin in patients with myocardial infarction by Cone and Plate(let) Analyzer
Hodgson A. - Thrombin causes an inflammatory cytokine response, which is inhibited by protein C, in both primary human monocytes and a monocyte (THP-1) cell line
  - NovoSeven does not produce an inflammatory reponse in a monocyte (THP-1) cell line or primary monocytes prestimulated with lipopolysaccharide
Hodivala-Dilke K. M. - Lineage-specific correction of a hemorrhagic disorder affecting platelets: gene therapy for Glanzmann thrombasthenia
Hoek F. J. - Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin layer chromatography
Hoek F. J. - Alterations in lipoprotein homeostasis during experimental and clinical sepsis in primates
Hoet P. H. M. - Role of pulmonary inflammation on the peripheral thrombotic risk following intratracheal instillation of diesel exhaust particles
  - Diesel exhaust particles deposited in the lung enhance thrombus formation in peripheral vessels in an in vivo model of vascular thrombosis
Hofbeck M. - Laborious way to an efficient prophylaxis: Homozygous prothrombin G20210A mutation in a neonate with cardiac diverticulum
  - Non-catheter related pulmonary artery thrombosis in a premature
Hoffet M. - Antiphospholipid/antiprotein antibodies and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case–control study
  - Anti-protein Z antibodies in women with abnormal pregnancies
Hoffman M. - Diet-induced hyperhomocysteinemia leads to a dysfibrinogenemia, elevated levels of plasminogen activator inhibitor-1 (PAI-1) and delayed clot lysis
  - A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function
  - The effect of temperature and pH on the activity of FVIIa: implications for the efficacy of high-dose FVIIa in hypothermic and acidotic patients
Hoffman M. - Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
Hoffman R. - Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
Hoffman M. - Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of hemophilia
Hoffman M. - Thrombin generation on the platelet surface
Hoffmann U. - Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
  - Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
  - The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
Hoffmann M. - New mutations in the fibrinogen genes of patients with dys, hypo- or fibrinogenemia
Hoffmann U. - MCP-1 as early marker for cell activation in septic patients
  - TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
Hoffmann M. - A mutation leading to a stop codon in the FVIII gene is the cause of severe canine Hemophilia A
Hofman A. - Genetic variability of von Willebrand factor and coronary heart disease: the Rotterdam Study
  - Association between genetic variability of von Willebrand factor and peripheral atherosclerosis: the Rotterdam Study
Hogenbirk K. - Evaluation of a bed-side device to assess the APTT for heparin monitoring in infants
Hogg P. J. - Protein–protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA-binding
Hogg D. - Evidence of transient endothelial activation in patients in sinus rhythm after electrical cardioversion of persistent atrial fibrillation
Hogg P. - The control of von Willebrand Factor multimer size by thrombospondin-1
Hogg K. - Comparison of the clinical utility of two D-dimer tests (IL Test and Simpify) in the diagnosis of pulmonary embolism
Hognestad A. - Interleukin-7-mediated inflammation in unstable angina – possible role of chemokines and platelets
Hoidal J. R. - Polymorphisms in the 5'UTR of the tissue factor (TF) gene are associated with differences in total and surface clotting activity and TF mRNA of endothelial cells
Holden N. - Platelet deposition in the microvasculature of transplanted human liver provides an adhesive substrate for the recruitment of recipient leukocytes
Holewijn S. - Venous outflow resistance can be used after acute deep-vein thrombosis as a screening test to identify patients at risk of the post-trombotic syndrome
  - IL-6 concentration in the acute phase of deep-vein thrombosis is a strong predictor of elevated venous outflow resistance as a proxy of post-trombotic syndrome
  - Compression bandaging in the acute phase of deep-vein thrombosis reduces symptoms but does not decrease venous outflow resistance and thrombosisscore as a proxy of the post-trombotic syndrome
Hollenbeck M. - Platelet receptor polymorphism HPA-1b and the G20210A mutation of the prothrombin-gene are risk determinants of vascular access thrombosis in hemodialysis patients
Hollestelle M. J. - Factor VIII expression in liver disease
Hollestelle M. J. - A mouse model for inhibitor development in mild hemophilia A
Hollon W. - An interactive coagulation laboratory database benefiting the entire Hemophilia Center team
  - An improved simpler method for using the ReFacto™ Laboratory Standard in monitoring patients receiving BDDrFVIII
Holm J. - Genetic variation at the human thrombomodulin promoter locus and prognosis after acute coronary syndrome
Holman B. - TAFI and diabetic nephropathy
Holmberg L. - Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
  - Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
  - An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
Holmes M. L. - Protein–protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA-binding
Holmstrøm H. - Family history of thromboembolism does not identify children with thrombophilia – A cross-sectional study
Holmström M. - Prophylaxis against bleeding with a factor VIII-von Willebrand factor concentrate in hemophilia A with high titer inhibitor
Holtkoetter O. - Normal arterial thrombus formation in integrin a2-deficient mice
Holzschuh I. - Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement
Hommais A. - Mutation of cysteines 1157 or 1234 located within the D3 domain of Von Willebrand Factor causes intracellular retention of high molecular weight multimers
Honda S. - Interaction of CD47 with SHPS-1 negatively regulates platelet function
  - Demonstration of activation of integrin aIIbb3 by inside-out signaling in a megakaryocytic cell line, CMK
Honda S. - Analysis of Arg-Gly-Asp contact sites in the av subunit of integrin avb3 employing single amino acid mutations
Honda Y. - DX-9065a, a direct factor Xa inhibitor prevents both arterial and venous thrombosis in rats via blocking prothrombinase complex activity – comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor
  - The effect of direct FXa inhibitor and direct thrombin inhibitor on TF induced DIC and venous thrombosis models in anesthetized rat – thrombin inhibitor enhance the platelet consumption in DIC model
Hong D. W. - Novel factor V mutations in three separate families resulting in factor V deficiency and bleeding
Hong G. - Consequences of expression of hepsin in murine vascular systems
Hong M. H. - A G-to-A mutation at -33 position in the promoter region of thrombomodulin gene and non-O blood group are associated with idiopathic venous thromboembolism: Taiwan Thrombophilia Study
Hong S. P. - A common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its association with a haplotype in the Korean population
Hong M. - Commercially available protein infusion solutions can be modified by nonenzymatic glycation which causes NFkappaB-dependent expression of procoagulant and inflammatory gene products
Hong S. H. - A collaborative study to establish a Korean standard for factor VIII : C concentrate
Hong C. M. - A collaborative study to establish a Korea National Biological Standard for antithrombin III concentrate
Hong S. H. - A collaborative study to establish a Korea National Biological Standard for antithrombin III concentrate
  - Prenatal diagnosis of dysprothrombinemia in an Iranian family
Hongeng S. - Successful use of recombinant activated factor VII for controlling bleeding in patients receiving invasive surgeries
Honma N. - Interaction of CD47 with SHPS-1 negatively regulates platelet function
Hooper W. C. - Comparison of cytokine-induced transcriptional factor response in HCAEC and HUVEC cell types
Hooper W. C. - The relationship between the TNF-308 polymorphism and Legg-Perthes disease
Hooper W. C. - Relationship of the Val34Leu polymorphism in the factor XIII gene with venous thromboembolism in American whites and blacks: the GATE study
Hooper W. C. - The relationship between genetic variants in peroxisome proliferator-activated receptors and venous thromboembolism in African-Americans and Caucasians
Hooper W. C. - Association of plasma homocysteine, serum folate, and red-blood cell folate with venous thromboembolism in American whites and blacks: the GATE study
Hoots W. K. - Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)
Hoots K. - A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
Hopmeier P. - Recurrent pregnancy loss between the 8th and 15th week of gestation is not associated with an increased frequency of protein Z deficiency
Hoppener M. R. - Day-care or short-stay surgery and venous thromboemolism: an overview
Hoppensteadt D. A. - Heparin-induced anti-platelet antibodies in very low birth-weight infants
Hoppensteadt D. - Heparinase I digestion of tinzaparin: a novel approach to neutralize the anti-coagulant and potential hemorrhagic effects of low molecular weight heparin
Hoppensteadt D. - Interaction of thrombolytic agents with argatroban: pharmacological implications
Hoppensteadt D. - Fibrinopeptide-A generation inhibition by anti-Xa drugs and its correlation with activated clotting time
  - Oral antithrombin agents comprise the regulatory functions of thrombin
  - Pharmacodynamics and pharmacokinetics of anti-Xa potency adjusted heparin derived oligosaccharides in nonhuman primates: implications in dosage optimization
Hoppensteadt D. A. - Serine proteases–mediated serotonin release and its inhibition by argatroban and other direct thrombin inhibitors: Implications in the control of thrombogenesis
Hoppensteadt D. - Lack dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation
Hoppensteadt D. - Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production
  - Influence of argatroban alone and combined with oral anticoagulants on the assessment of coagulation factors
  - The irrelevance of International Normalized Ratio in the monitoring of anti-IIa and anti-Xa drugs
Hoppensteadt D. A. - Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials
Hoppensteadt D. - Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis
Hoppensteadt D. A. - Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications
Hoppensteadt D. - Nitric oxide levels are up-regulated in patients with malignancy associated hypercoagulable state
  - Malignancy-related thrombotic state is independent of defects in Factor V Leiden, prothrombin 20210 and MTHFR. Results from the initial profiling of cancer patients entering in a secondary prevention of venous thrombosis with enoxaparin (ONCENOX)
  - Species dependence on nitric oxide generation: pharmacological implications on animal modeling
  - Lower limb trauma is associated with a moderate risk of thrombosis caused by sustained release of tissue factor despite early functional mobilization
  - Prevalence of anti-Erythropoietin antibodies in end stage renal disease patients treated with recombinant Erythropoietin
  - Activated clotting time guided dosage optimization of a low molecular weight heparin (tinzaparin) for surgical and interventional indications
  - Molecular-weight dependence on the inhibition of procarboxypeptidase U by heparin and a polydeoxyribonucleotide derived antithrombotic agent (Defibrotide)
Hoppensteadt D. A. - Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins
Hoppensteadt D. - Inhibition of procarboxypeptidase U by tinzaparin. A potential mechanism of its profibrinolytic actions
  - Non-coagulant variants of thrombin are capable of activating procarboxypeptidase U
Hoppensteadt D. A. - Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications
Hoppensteadt D. - Elevated soluble thrombomodulin levels in patients with acute coronary syndrome: down-regulation by anticoagulant dosage of low molecular weight heparins
Hordijk P. - The small GTP-binding protein Ral is involved in cAMP-mediated release of VWF from endothelial cells
Hordijk P. L. - Real-time imaging of the dynamics and secretary behavior of Weibel–Palade bodies
Hordijk P. - a4 integrins and P-selectin mediate rolling and initial attachment of platelet-monocyte complexes to activated endothelium under flow conditions
Horellou M. H. - Risk of pregnancy-related venous thromboembolism (VTE) in 60 hereditary AT-deficient women from 45 families: study of 164 pregnancies
Horie S. - Oxidation products of common phospholipid specifically impair the activity and the reactivity of tissue factor pathway inhibitor
Horie S. - Ligand for peroxisome proliferator-activated receptor-a (PPARa) Down-regulates tumor necrosis factor - a-induced pro-coagulant activation of tissue factor through inhibition of ap-1-dependent gene transcription in human endothelial cells
Horie S. - Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family
Horie S. H. - Oxidized phospholipids in oxidized LDL down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RAR
Horii K. - Characterization and preliminary crystallographic studies of EMS16, an antagonist of collagen receptor (GPIa/IIa) from the venom of Echis multisquamatus
  - Crystal structure of a disintegrin from snake venom containing a cell adhesion recognition sequence RGD
Horn A. - Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after major abdominal surgery: the FAME study
Horrow J.C. - Rates of recurrent thromboembolism and bleeding in venous thromboembolism patients treated with long-term LMWH
Horsewood I. - Multimerin supports platelet adhesion by functioning as an RGD ligand for platelet integrin receptors
Horstkotte D. - Influence of platelet glycoprotein IIIa PlA polymorphism on mean platelet volume and vWF after coronary stent implantation
  - The G allele of IL-6–174G/C polymorphism is a risk factor for restenosis after coronary stent implantation by increased inflammation and platelet activation
Horstman L. - Tissue factor activity is controlled by its inhibitor and redox state: Findings in endothelial microparticles, monocytes, and a porcine trauma model
Horstman L. L. - Life-threatening thrombosis following splenectomy in a patient with ITP: successful management with anticoagulation and danazol
Horstman L. - Successful outcome of rituximab therapy for spontaneous refractory high titer FVIII inhibitors
Hosokawa K. - M-thrombin (Tris-coupled thrombin) is a novel potent agonist of platelet activation with minimum effect on clot formation
  - Zinc chelation by histidine-rich glycoprotein is essential for its interaction with coagulation and fibrinolysis factors and its ability to enhance fibrinolysis
Ho-Tin-Noé B. - Effect of apolipoprotein(a) on plasminogen activation-induced apoptosis of vascular smooth muscle cells
Houdijk W. H. - Frequency of biphasic transmittance waveform in the APTT coagulation assay in the patients with underlying diseases of DIC
Houel R. - Aspirine resistance: a particularly high prevalence in patients after ventricular assist device implantation
Hough C. - The type 1/type 2M von Willebrand disease dilemma: findings from the Canadian Type 1 VWD study
Hough Ahcdc - The type 1/type 2M von Willebrand disease dilemma: findings from the Canadian Type 1 VWD study
Hough C. - The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy
Hough C. - A type 2A (Group II) von Willebrand disease mutation (Leu1503Glu) associated with a minimal loss of high molecular weight von Willebrand factor (VWF) multimers
Hough C. - An ancient von Willebrand Disease (VWD) mutation that associates with a common haplotype in ~14% of type 1 VWD patients
  - Clear familial co-segregation of the type 1 von Willebrand disease phenotype and VWF haplotypes in the Canadian type 1 VWD study
Houllier A. - Stability of 19 mutated recombinant von Willebrand factor to von Willebrand factor-cleaving protease (ADAMTS13)
  - Identification of the bitiscetin-binding site on the von Willebrand factor A3-domain. Comparison to the collagen-binding site
Housan L. V. - Does DVT exist in Asia? – The AIDA study (assessment of the incidence of Deep Vein Thrombosis in Asia following major orthopedic surgery): study rationale and interim results
Howard T. E. - Phospholipid-dependent impairment of the inhibitory properties of hirudin: the cause of false-positive assays for lupus anticoagulants (LAs)
Howard I. R. - Platelet glycoprotein Iba VNTR polymorphisms: association with thromboembolic diseases
Howard T. E. - Functional resequencing of the factor IX (f-IX) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-IX activity levels in the GAIT project
  - Terminal intron splicing of the prothrombin premRNA is associated with 3'-cleavage site recognition and polyadenylation
Howard T. E. - Functional re-sequencing of the factor VIII (f-VIII) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-VIII activity levels in the Gait Project
Howard M. A. - Long-term outcomes following recovery from thrombotic thrombocytopenic purpura – hemolytic uremic syndrome (TTP-HUS) measured by health-related quality-of-life (QOL) assessments
Howarth N. - Diagnosing pulmonary embolism with clinical assessment, d-dimer, venous ultrasound and helical computed tomography: a multicenter management study
Howarth D. J. - Associations of hemostatic variables with changes in anthropometric measures and metabolic variables in the morbidly obese
Howe T. S. - Radioisotopic synovectomy and haemophilic arthropathy in Asians: a retrospective study
Howe B. - Reliability of patient self-testing and point-of-care testing with the Harmony (TM) INR monitoring system: a 3-year study
  - Maintenance of patient vs. professional competence with patient self testing of the INR – a 6-year experience
Howes P. - Correlation of the serum ferritin (SF) levels with cholesterol and body mass index (BMI) in patients with advanced atherosclerosis
Hoyano Y. - Effect of KFA-1982, a new orally active factor Xa inhibitor, in a rabbit venous thrombosis model
Hoylaerts M. F. - Diesel exhaust particles deposited in the lung enhance thrombus formation in peripheral vessels in an in vivo model of vascular thrombosis
Hoylaerts M. - Role of pulmonary inflammation on the peripheral thrombotic risk following intratracheal instillation of diesel exhaust particles
Hoylaerts M. F. - Platelet recruitment in vivo to injured blood vessels is not prevented by GPIIb/IIIa antagonism
  - Glycoprotein Ib and integrin a IIbb 3 contribute to GPVI-dependent vWF-collagen induced thrombus formation under flow
  - P2X1-induced activation of Ca2+ calmodulin leads to myosin light chain and ERK2 phosphorylation in human platelets
  - Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype
Hoylaerts M. - The Gs agonist PACAP(1–38) is a physiological inhibitor of platelet aggregation and megakaryocyte maturation
Hoylaerts M. F. - Functional polymorphisms in the paternally expressed XLas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation resulting in platelet Gs hyperfunction
Hoylaerts M. - A new Von Willebrand ristocetin cofactor activity assay based on plasma glycocalicin
Hoylarts M. F. - A new platelet activation marker specific for activated integrin alpha2beta1: monoclonal antibody IAC-1
Hrachovinova I. - Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe haemophilia A in the Czech Republic
  - The anti-thrombin variant -6Arg is a silent mutation
Hrafnkelsdottir T. - Anti-hypertensive treatment restores impaired local fibrinolysis in essential hypertension
Hsiao G. - Inhibitory effects of andrographolide on lipopolysaccharide-induced tissue factor expression in human monocytic THP-1 cells
Hsiao G. - Morphine-potentiated platelet aggregation in in vitro and platelet plug formation in in vivo experiments
Hsiao G. - Inhibitory mechanisms of magnesium sulfate on platelet aggregation in in vitro and in vivo experiments
Hsiao G. - A novel anti-oxidant, octyl caffeate, suppresses LPS/IFN-g-induced iNOS gene expression in rat aortic smooth muscle cells
Hsiao G. - Comparison of the binding character of triflavin on resting and activated aIIbb3 integrin in human platelets by electron microscopy
Hsiech Y. J. - To evaluate the mechanism of neutrophil activation caused by a Cox-2 inhibitor-celecoxib
Hsieh K. - Impact of platelet glycoprotein Ibalpha Kozak polymorphism on risk of ischemic cerebrovascular events
Hsu S. C. - Novel mutations in the factor X gene of a Taiwanese factor X-deficient patient
Hsu T.-C. - Recombinant factor VIII C1C2 domain expressed in E. coli
Hsu Y. C. - Expression of full-length recombinant factor VIII by doxycycline-controlled expression system
Hsueh S. Y. - A G-to-A mutation at -33 position in the promoter region of thrombomodulin gene and non-O blood group are associated with idiopathic venous thromboembolism: Taiwan Thrombophilia Study
Hu W. - Non-lysine-analog plasminogen modulators: promotion of autocatalytic generation of plasmin(ogen) fragments with angiostatin-like activity and inhibition of tumor growth in vivo
Hu H. - Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins
Hu H. - Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus
  - Enhanced platelet and leukocyte activation by strenuous exercise in type I diabetes mellitus
Hu H. - Platelet function and inflammatory markers in patients with type 1 diabetes with and without microvascular complications
  - Clopidogrel treatment provides limited protection against exercise-induced platelet-leukocyte conjugation
  - Clopidogrel treatment reduces platelet activity in vivo, but does not counteract exercise-induced platelet activation
Hu Y. - b3-integrin deficiency and antibody-mediated b3-integrin inhibition have paradoxical effects on murine smooth muscle cell proliferation and the development of intimal hyperplasia after vascular injury
Huang H. C. - Modulation of thrombin signaling by internalization of thrombin and thrombomodulin complex
Huang T. F. - A snake venom metalloproteinase reduces neutrophil-platelet adhesion through down-regulation of PSGL-1 expression
Huang F. Q. - The study on phenotype and genotype of Protein C in a Chinese family with hereditary Protein C deficiency
Huang T. F. - Gramicetin: a new agonist that activates platelets via glycoprotein Ib ligation
Huang T. F. - Aggretin, a snake venom-derived endothelial integrin a 2b 1 agonist, induces angiogenesis in vitro and in vivo via expression of vascular endothelial growth factor
Huang C. C. - Expression of full-length recombinant factor VIII by doxycycline-controlled expression system
Huang H. Y. - Consequences of expression of hepsin in murine vascular systems
Huang P. H. - Consequences of expression of hepsin in murine vascular systems
Hubbard A. - Estimation of von Willebrand factor: collagen binding in therapeutic concentrates
  - A multicenter study on the potency estimation of ReFacto
Hubbard G. P. - A role for the thiol isomerase protein P5 in platelet function
Hubbard G. - The inhibitory action of quercetin on GPVI-mediated platelet signaling and activation
Hubé F. - Quantitative evaluation of TFPI-2 and MMP-9 expression in nonsmall cell lung cancer
Hubé F. - Transcriptional silencing of TFPI-2 gene by hypermethylation of the promoter in choriocarcinoma cells
  - Demonstration of a tissue factor pathway inhibitor-2 (TFPI-2) mRNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas
Huber K. - A microsatellite polymorphism in the Heme Oxygenase – 1 gene promoter is associated with increased serum bilirubin and HDl levels but not with a decreased risk for coronary artery disease
  - The effect of pretreatment with clopidogrel on platelet and coagulation activation in patients with stable angina undergoing elective coronary stenting
Huber W. - The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies
Huber R. - Mechanisms of conformational activation of prothrombin by staphylocoagulase and fibrinogen substrate recognition
Hug M. I. - Arterial thromboembolic complications in children
Hugel B. - Importance of beta-2 glycoprotein I in the lupus anticoagulant cofactor effect: a case report
Hughan S. C. - Phosphoinositide 3-kinase beta (PI3Kb): a novel target for antithrombotic therapy
Hughan S. C. - Integrin aIIbb3 outside-in calcium signals sustain platelet–fibrinogen interactions under flow
Hughan S. C. - Role of the Type Ia PI 3-kinase p110beta isoform in integrin alpha(IIb)beta(3) bi-directional signaling
Hughes Q. W. - Prediction and prevention of thrombosis during pregnancy and oestrogen use
Hughes G. R. V. - Validation of the Taipan snake venom assay in routine practice to assess lupus anticoagulant status in patients being assessed for lupus anticoagulant and not receiving oral anticoagulant
Huguet H. - Extracorporeal adsorption of Factor VIII antibodies on randomly functionalized polystyrene resins
Huhle G. - Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
  - The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
  - Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
  - MCP-1 as early marker for cell activation in septic patients
  - TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
Huijboom K. - a4 integrins and P-selectin mediate rolling and initial attachment of platelet-monocyte complexes to activated endothelium under flow conditions
Huisman M. V. - The role of spiral CT in alternative diagnosis in patients with clinical suspicion of pulmonary embolism
Huisman M. V. - Common genetic abnormalities in blood coagulation (Factor V Leiden, prothrombin G20210A) increase the incidence of central vein catheter related thrombosis
  - Relation of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis with the low molecular weight heparin Certoparin or unfractionated heparin
  - A prospective implementation study of out-patient treatment with subcutaneous low-molecular-weight heparin and oral anti-coagulants in patients with deep venous thrombosis in routine clinical practice
  - Atorvastatin strongly reduces C-reactive protein, but shows less marked effect on other prognostic inflammatory markers
  - Decrease of thrombophilia variables by aggressive vs. conventional atorvastatin treatment in patients with type 2 diabetes mellitus
  - The assessment of pretest probability in patients with suspected Deep-Vein Thrombosis is of great value in nonacademic teaching hospitals
Huisman P. M. - The assessment of pretest probability in patients with suspected Deep-Vein Thrombosis is of great value in nonacademic teaching hospitals
Huisman M. V. - Prescribing anticoagulant prophylaxis in patients with hematological or solid tumor malignancies and central vein catheters: a nationwide survey
Huisman M.V. - Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study
Huismann M. - Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
Huisse M. G. - Specific phosphatidylserine exposure and microparticules shedding induced by a synthetic peptide
Huizinga E. - Identification of the bitiscetin-binding site on the von Willebrand factor A3-domain. Comparison to the collagen-binding site
Hull R. - A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer
Hull R. D. - Tracking the uptake of evidence: two decades of hospital practice trends for diagnosing deep vein thrombosis and pulmonary embolism
Hull R. D. - D-dimer for the exclusion of acute deep venous thrombosis and pulmonary embolism: a systematic review
Hull R. D. - Does rebound exist? A comparison of venous thromboembolic event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin vs. warfarin sodium
Hull R. - Non-invasive detection of proximal DVT using bilateral compression ultrasound: methodology for the EXCLAIM study
Hull R. D. - Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement
  - Timing of initial administration of prophylaxis against deep vein thrombosis in patients following hip or knee surgery
Hull R. - Should prophylaxis be continued after discharge in surgical patients?
Hull R. D. - A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by Warfarin Sodium
Hull R. - Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study
Hulstein J. J. J. - The sensitivity and specificity of ADAMTS13 activity for primary thrombotic thrombocytopenic purpura
Humar A. - Successful liver transplantation in a hemophilia A patient with high titer factor VIII inhibitor
Humpert P. M. - Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception
Humpert P. - Commercially available protein infusion solutions can be modified by nonenzymatic glycation which causes NFkappaB-dependent expression of procoagulant and inflammatory gene products
Humphries S. E. - A thrombomodulin (TM) gene promoter variant (TM-33G > A) in type 2 diabetes
  - Polymorphisms in the thrombomodulin gene as risk factors for myocardial infarction (HIFMECH study)
  - Soluble endothelial cell markers (sTM, sEPCR and sVWF) in type 2 diabetes
Humpich M. - Lupus anticoagulant in systemic lupus erythematodes as risk factor for cryptogenic stroke
Humpich M. - Detection of lupus anticoagulant: development of a new precise, sensitive and specific aPTT-based assay
Hunt B. J. - The relationship between APTT and lupus anticoagulants
  - Validation of the Taipan snake venom assay in routine practice to assess lupus anticoagulant status in patients being assessed for lupus anticoagulant and not receiving oral anticoagulant
  - Performance characteristics of the VIDAS and IL test d-dimer (d-d) assays as exclusionary tests for venous thromboembolism (VTE) after acute ischemic stroke (AIS)
  - The relationship between acute ischemic stroke (AIS) per se and plasma D-D (D-D) levels
  - Recognized and unrecognized clinical venous thromboembolism (VTE) after acute ischemic stroke (AIS): a prospective study using magnetic resonance direct thrombus imaging (MRDTI)
  - The relationship between plasma D-dimers (D-d) and thrombus load in patients with deep vein thrombosis (DVT) after acute ischaemic stroke (AIS): a prospective study using magnetic resonance direct thrombus imaging (MRDTI)
Hunter J. - Antithrombotic effects of selective P2Y1 and P2Y12 antagonists in anesthetized rats
Hunter A. - ROTEG thromboelastography: sample stability and results in warfarinized and heparinized patients
Huntington J. - Mechanisms of glycosaminoglycan activation of the serpins in hemostasis
Huntington J. A. - Conformational basis of homozygous heparin cofactor II deficiency confirms critical role of P17 glutamate in serpins
  - Mutations in the shutter region of anti-thrombin result in severe episodic thrombosis and unlike other serpins in formation of disulfide-linked dimers
  - Role of Anti-thrombin residue Glu381 (P13)
Huntington J. - The molecular basis of thrombin allostery revealed by a 1.8-Å structure of the ‘slow’ form
Huppertz-Helmhold S. - Assessment of the inhibitor development in previously untreated patients (PUPs) suffering from hemophilia A treated with rFVIII: continuous evaluation of the German Pharmacovigilance Evaluation (PE) with ReFacto & reg
Hurd C. - Teicoplanin-dependent platelet antibodies as a cause of severe thrombocytopenia
Hurlen M. - Levels of soluble tissue factor are related to future clinical events in patients with previous myocardial infarction
  - Serum levels of the anti-inflammatory cytokine interleukin-10 are inversely associated with future events in patients with previous acute myocardial infarction
  - The influence of warfarin on plasma levels of soluble tissue factor, prothrombin fragment 1 + 2 and D-dimer in patients after acute myocardial infarction
Hurley J. S. - Health care costs and clinical outcomes in patients on chronic oral anti-coagulation undergoing perioperative bridging with low-molecular-weight heparin vs. unfractionated heparin
Hurlstone A. - Ischemia induces early and enhanced expression of a new transcription factor (6A3-5) in human and rat kidney vascular smooth muscle cells
  - Structural and functional characterization of a new transcription factor (6A3-5) potentially implicated in changes of smooth muscle cells phenotype
Hursting M. J. - The predictors of clinical outcome in patients with heparin-induced thombocytopenia
Hurtado B. - PROS1 mutations that introduce a premature termination codon explain protein S deficiency by nonsense-mediated mRNA decay
Hurvitz A. - Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina
Hussain M. M. - The platelet adhesion receptor, F11R (a.k.a. JAM-1), is critical for the initiation of plaque formation, thrombosis and atherosclerosis
  - Phosphorylation and expression of the extracellular domain of the platelet adhesion receptor, F11R (a.k.a. junctional adhesion molecule, JAM-1)
Hutchings A. - An economic evaluation of the costs and benefits of heparin rationalisation in a UK hospital
Hutchinson K. - Incidental pulmonary embolism in patients with cancer
Hutchison S. - A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
Hutten B. A. - The optimal duration of treatment with vitamin K antagonists in patients with a first episode of venous thromboembolism: a decision analytic approach
  - The clinical outcome of pediatric venous thrombo-embolic disease in one tertiary centre
  - Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremities: survival, risk factors and post–thrombotis syndrome
  - High levels of coagulation factors IX or XI: risk factors for pulmonary embolism?
Hutten B. A. - Age and first INR after standard initiation of oral anti-coagulant therapy with acenocoumarol predict the maintenance dosage
Hutten B. A. - CYP2C9 polymorphisms have differential effects on the quality of acenocoumarol treatment
  - CYP2C9 polymorphisms have differential effects on acenocoumarol metabolism, but do not increase bleeding risk
  - Optimal intensity of oral anti-coagulant therapy in patients with mechanical heart valves
  - Relation between compliance and quality of treatment with vitamin K antagonists
Huyghe T. - Interest of diluted Russel viper venom time (dRVVT) in determining “pathogenic” lupus anticoagulants
Hynes R. - Integrins and angiogenesis
Hynes R. O. - Autoantibodies to recombinant PSI domain but not to cytoplasmic tail of beta3 integrin cause immune thrombocytopenia
  - Lineage-specific correction of a hemorrhagic disorder affecting platelets: gene therapy for Glanzmann thrombasthenia
Hyun Kyung K. - Circulating vascular cell adhesion molecule-1 in patients with operable breast cancer